

# Stefano Kim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8546553/publications.pdf>

Version: 2024-02-01

61  
papers

3,211  
citations

430754

18  
h-index

155592

55  
g-index

66  
all docs

66  
docs citations

66  
times ranked

4805  
citing authors

#	ARTICLE	IF	CITATIONS
1	5'-Triphosphate RNA Is the Ligand for RIG-I. <i>Science</i> , 2006, 314, 994-997.	6.0	2,094
2	Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 1094-1106.	5.1	108
3	Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. <i>British Journal of Cancer</i> , 2014, 110, 2821-2828.	2.9	89
4	Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial. <i>Clinical Cancer Research</i> , 2019, 25, 2109-2115.	3.2	65
5	Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review. <i>Cancer Medicine</i> , 2014, 3, 1502-1511.	1.3	61
6	DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma. <i>Annals of Oncology</i> , 2013, 24, 3045-3050.	0.6	50
7	Cabazitaxel. <i>Drugs</i> , 2011, 71, 1251-1258.	4.9	44
8	Impact of STAT3 Phosphorylation on the Clinical Effectiveness of Anti-EGFR-Based Therapy in Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2013, 12, 28-36.	1.0	35
9	Metronomic cyclophosphamide: An alternative treatment for hepatic epithelioid hemangioendothelioma. <i>Journal of Hepatology</i> , 2013, 58, 1254-1257.	1.8	33
10	St. Louis Encephalitis in Argentina: the First Case Reported in the Last Seventeen Years. <i>Emerging Infectious Diseases</i> , 2003, 9, 271b-273.	2.0	31
11	In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial. <i>Oncolmmunology</i> , 2018, 7, e1424673.	2.1	27
12	Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a multicentric study. <i>BMC Cancer</i> , 2016, 16, 823.	1.1	25
13	Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097535.	1.4	24
14	Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial. <i>BMC Cancer</i> , 2020, 20, 352.	1.1	24
15	Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy. <i>BMC Gastroenterology</i> , 2014, 14, 143.	0.8	23
16	Evaluation of a 36 Gy elective node irradiation dose in anal cancer. <i>Radiotherapy and Oncology</i> , 2015, 116, 197-201.	0.3	23
17	Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients. <i>European Journal of Cancer</i> , 2021, 150, 1-9.	1.3	23
18	A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202). <i>ESMO Open</i> , 2022, 7, 100529.	2.0	23

#	ARTICLE	IF	CITATIONS
19	Esophageal intramural pseudodiverticulitis.. Radiology, 1989, 173, 418-418.	3.6	22
20	Hemodialysis does not affect everolimus pharmacokinetics: two cases of patients with metastatic renal cell cancer. Annals of Oncology, 2012, 23, 2992-2993.	0.6	22
21	Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study). BMC Cancer, 2017, 17, 574.	1.1	22
22	Anti-Telomerase CD4+ Th1 Immunity and Monocytic-Myeloid-Derived-Suppressor Cells Are Associated with Long-Term Efficacy Achieved by Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) in Advanced Anal Squamous Cell Carcinoma: Translational Study of Epitopes-HPV01 and 02 Trials. International Journal of Molecular Sciences, 2020, 21, 6838.	1.8	21
23	Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice. Clinical Medicine Insights: Oncology, 2016, 10, CMO.S38335.	0.6	19
24	LBA42 POD1UM-202: Phase II study of retifanlimab in patients (pts) with squamous carcinoma of the anal canal (SCAC) who progressed following platinum-based chemotherapy. Annals of Oncology, 2020, 31, S1170-S1171.	0.6	19
25	Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels. BMC Cancer, 2013, 13, 611.	1.1	18
26	Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate Cancer. Clinical Medicine Insights: Oncology, 2013, 7, CMO.S7256.	0.6	18
27	Docetaxel, Cisplatin, and 5-Fluorouracil as perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma. Cancer Medicine, 2016, 5, 3085-3093.	1.3	16
28	Molecular description of <sc>ANGPT2</sc> associated colorectal carcinoma. International Journal of Cancer, 2020, 147, 2007-2018.	2.3	15
29	The impact of taxane-based preoperative chemotherapy in gastroesophageal signet ring cell adenocarcinomas. Journal of Hematology and Oncology, 2015, 8, 52.	6.9	14
30	Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological score. International Journal of Cancer, 2016, 139, 2325-2335.	2.3	14
31	Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST). European Journal of Cancer, 2019, 107, 46-52.	1.3	14
32	Prognostic Value of Angiopoietin-2 for Death Risk Stratification in Patients with Metastatic Colorectal Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 603-612.	1.1	12
33	Feasibility of health-related quality of life (HRQoL) assessment for cancer patients using electronic patient-reported outcome (ePRO) in daily clinical practice. Quality of Life Research, 2021, 30, 3255-3266.	1.5	12
34	Present and Future Research on Anal Squamous Cell Carcinoma. Cancers, 2021, 13, 3895.	1.7	12
35	Primary Linitis Plastica of the Rectum: Focus on Magnetic Resonance Imaging Patterns and Treatment Options. American Journal of Case Reports, 2015, 16, 581-585.	0.3	10
36	Successful Treatment of a Granulocytic Sarcoma of the Uterine Cervix in Complete Remission at Six-Year Follow-Up. Journal of Oncology, 2010, 2010, 1-3.	0.6	9

#	ARTICLE	IF	CITATIONS
37	Perioperative docetaxel, cisplatin, and 5-fluorouracil compared to standard chemotherapy for resectable gastroesophageal adenocarcinoma. <i>European Journal of Surgical Oncology</i> , 2017, 43, 218-225.	0.5	9
38	RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study. <i>Cancer Imaging</i> , 2019, 19, 85.	1.2	9
39	FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer. <i>World Journal of Clinical Oncology</i> , 2018, 9, 110-118.	0.9	9
40	Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 141-150.	1.1	8
41	Efficacy and Safety of Bevacizumab Combined With First-Line Chemotherapy in Elderly (>=75 Years) Patients With Metastatic Colorectal Cancer: A Real-World Study. <i>Clinical Colorectal Cancer</i> , 2020, 19, e100-e109.	1.0	7
42	FOLFIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study. <i>World Journal of Gastrointestinal Oncology</i> , 2020, 12, 332-346.	0.8	7
43	Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 231-238.	0.9	6
44	A new anti-mesothelin antibody targets selectively the membrane-associated form. <i>MAbs</i> , 2017, 9, 567-577.	2.6	6
45	Personalized identification of tumor-associated immunogenic neoepitopes in hepatocellular carcinoma in complete remission after sorafenib treatment. <i>Oncotarget</i> , 2018, 9, 35394-35407.	0.8	6
46	Exposure-response analysis of Raltitrexed assessing liver toxicity. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1327-1337.	1.1	5
47	Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial. <i>Digestive and Liver Disease</i> , 2021, 53, 1254-1259.	0.4	5
48	Complete Response to Aflibercept-FOLFIRI in One Patient With Colorectal Cancer Refractory to Bevacizumab-FOLFOX: A Possible Autocrine Vascular Endothelial Growth Factor Receptor 2-Related Mechanism. <i>Clinical Colorectal Cancer</i> , 2016, 15, e229-e234.	1.0	4
49	SALL4 oncogene is an immunogenic antigen presented in various HLA-DR contexts. <i>Oncolimmunology</i> , 2018, 7, e1412030.	2.1	4
50	How to Choose the Right Treatment for Patients With Advanced Squamous Cell Carcinoma in the Absence of a Comparative Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3973-3974.	0.8	4
51	Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies. <i>European Journal of Cancer</i> , 2022, 162, 138-147.	1.3	4
52	A simple and fast LC-MS/MS method with a very high sensitivity for the measurement of raltitrexed in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1060, 240-246.	1.2	3
53	Myeloid derived suppressor cells but not regulatory T cells are associated with adaptive immunity and clinical outcomes in anal squamous cell carcinoma. <i>Annals of Oncology</i> , 2019, 30, v770-v771.	0.6	3
54	Selecting the right chemotherapy in first-line advanced squamous cell carcinoma of the anus. <i>Annals of Oncology</i> , 2022, 33, 349-350.	0.6	3

#	ARTICLE	IF	CITATIONS
55	Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II study. <i>European Journal of Cancer</i> , 2022, 168, 99-107.	1.3	3
56	Updated data of epitopes-HPV02 trial and external validation of efficacy of DCF in prospective epitopes-HPV01 study in advanced anal squamous cell carcinoma. Pooled analysis of 115 patients. <i>Annals of Oncology</i> , 2019, 30, v203.	0.6	2
57	Real-world safety and effectiveness of regorafenib in metastatic colorectal cancer: the French CORRELATE cohort. <i>Future Oncology</i> , 2021, 17, 3343-3353.	1.1	2
58	Treatment-Induced Acute Leukaemia after Major Response to Cyclophosphamide-Based Metronomic Chemotherapy in Refractory Heavily Pre-Treated Prostate Cancer. <i>Journal of Cancer Therapy</i> , 2013, 04, 165-169.	0.1	2
59	Physicians's satisfaction with health-related quality of life (HRQoL) assessment in daily clinical practice using electronic patient-reported outcome (ePRO) for cancer patients. <i>Annals of Oncology</i> , 2019, 30, v729-v730.	0.6	1
60	Docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: A phase II study of French interdisciplinary GERCOR and FFCD Groups (Epitopes-HPV02 study). <i>Annals of Oncology</i> , 2017, 28, v181.	0.6	0
61	Interest of the Addition of Taxanes to Standard Treatment in First-Line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients. <i>Frontiers in Oncology</i> , 2022, 12, 763926.	1.3	0